The patient was enrolled in a clinical trial combining the PARP inhibitor olaparib with the PD-L1 inhibitor durvalumab due to the germline and somatic findings (Study ID: ACTRN12617001000392).34 The patient had a partial response by RANO 6 weeks after starting treatment (Figure 3B), with clinical and radiological improvement after 2.5 months (Figure 3C) and near-complete tumor response after 5 months of therapy (Figure 3D), suggesting the potential impact of germline HR variants on clinical response to PARP inhibition in DMG patients. Here, CD274 is linked to neoplasm.